{"id":36185,"date":"2025-06-27T16:35:36","date_gmt":"2025-06-27T08:35:36","guid":{"rendered":"https:\/\/flcube.com\/?p=36185"},"modified":"2025-06-27T16:35:37","modified_gmt":"2025-06-27T08:35:37","slug":"mabwell-bioscience-partners-with-calico-life-sciences-on-9mw3811-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36185","title":{"rendered":"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development"},"content":{"rendered":"\n<p>China-based Mabwell (Shanghai) Bioscience Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>) is set to enter into a licensing agreement with US-headquartered Calico Life Sciences LLC regarding its 9MW3811, an anti-IL-11 humanized monoclonal antibody (mAb) being studied in clinical trials for fibrosis and tumors.<\/p>\n\n\n\n<p><strong>Agreement Details<\/strong><br>Under the terms of the agreement, Calico will secure exclusive global rights (excluding Greater China) to develop, manufacture, and commercialize 9MW3811. In return, Mabwell will receive an upfront payment of USD 25 million from Calico. Additionally, Mabwell is eligible for milestone payments totaling up to USD 571 million, contingent upon the achievement of specific development, regulatory, and commercial milestones. The agreement also includes provisions for tiered royalties based on the net sales of the product.<\/p>\n\n\n\n<p><strong>Drug Development<\/strong><br>9MW3811 is currently undergoing clinical studies in China, Australia, and the US. The drug is being investigated for its potential applications in the treatment of fibrosis and various tumors, with the goal of addressing significant unmet medical needs in these areas.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688062_20250627_WAAJ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688062_20250627_WAAJ.\"><\/object><a id=\"wp-block-file--media-203e5316-4f13-4895-bcf3-a541584d8dd1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688062_20250627_WAAJ.pdf\">688062_20250627_WAAJ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688062_20250627_WAAJ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-203e5316-4f13-4895-bcf3-a541584d8dd1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36188,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[674,16,118,1129],"class_list":["post-36185","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-calico-life-sciences","tag-cancer","tag-mabwell-bioscience","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing agreement with US-headquartered Calico Life Sciences LLC regarding its 9MW3811, an anti-IL-11 humanized monoclonal antibody (mAb) being studied in clinical trials for fibrosis and tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36185\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development\" \/>\n<meta property=\"og:description\" content=\"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing agreement with US-headquartered Calico Life Sciences LLC regarding its 9MW3811, an anti-IL-11 humanized monoclonal antibody (mAb) being studied in clinical trials for fibrosis and tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36185\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-27T08:35:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T08:35:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2707.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development\",\"datePublished\":\"2025-06-27T08:35:36+00:00\",\"dateModified\":\"2025-06-27T08:35:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185\"},\"wordCount\":173,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2707.webp\",\"keywords\":[\"Calico Life Sciences\",\"Cancer\",\"Mabwell Bioscience\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36185#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36185\",\"name\":\"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2707.webp\",\"datePublished\":\"2025-06-27T08:35:36+00:00\",\"dateModified\":\"2025-06-27T08:35:37+00:00\",\"description\":\"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing agreement with US-headquartered Calico Life Sciences LLC regarding its 9MW3811, an anti-IL-11 humanized monoclonal antibody (mAb) being studied in clinical trials for fibrosis and tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36185\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2707.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2707.webp\",\"width\":1080,\"height\":608,\"caption\":\"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36185#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing agreement with US-headquartered Calico Life Sciences LLC regarding its 9MW3811, an anti-IL-11 humanized monoclonal antibody (mAb) being studied in clinical trials for fibrosis and tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36185","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development","og_description":"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing agreement with US-headquartered Calico Life Sciences LLC regarding its 9MW3811, an anti-IL-11 humanized monoclonal antibody (mAb) being studied in clinical trials for fibrosis and tumors.","og_url":"https:\/\/flcube.com\/?p=36185","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-27T08:35:36+00:00","article_modified_time":"2025-06-27T08:35:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2707.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36185#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36185"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development","datePublished":"2025-06-27T08:35:36+00:00","dateModified":"2025-06-27T08:35:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36185"},"wordCount":173,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36185#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2707.webp","keywords":["Calico Life Sciences","Cancer","Mabwell Bioscience","SHA: 688062"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36185#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36185","url":"https:\/\/flcube.com\/?p=36185","name":"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36185#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36185#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2707.webp","datePublished":"2025-06-27T08:35:36+00:00","dateModified":"2025-06-27T08:35:37+00:00","description":"China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing agreement with US-headquartered Calico Life Sciences LLC regarding its 9MW3811, an anti-IL-11 humanized monoclonal antibody (mAb) being studied in clinical trials for fibrosis and tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36185#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36185"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36185#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2707.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2707.webp","width":1080,"height":608,"caption":"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36185#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2707.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36185"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36185\/revisions"}],"predecessor-version":[{"id":36189,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36185\/revisions\/36189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36188"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}